Healthcare
Live Price
Offline$53.22
+3.34% today
1Y Change
+38.24%
Window
Jun 23, 2025 → Jun 16, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
TG Therapeutics, Inc. (TGTX) is a Healthcare stock with a market cap of $5.40B and listed on NASDAQ. The stock last traded around $53.22 and up 38.2% across the available one-year price window (Jun 23, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of +87.3%, EPS growth of +1837.5%, a dividend yield of 0.0%. What stands out right now is revenue +87.3%, EPS +1837.5%, free cash flow +38.4% with operating margin 20.0% and ROIC 13.5%. Valuation already assumes a fairly strong business story at P/E 10.8 and price/sales 8.8. Stock Foundry combines TGTX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TGTX
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TGTX Max Drawdown
-32.66%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TGTX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$6.7M
+140.2% YoY
FY Net Income
-$348.1M
-55.5% YoY
Free Cash Flow
-$296.0M
-68.0% YoY
Revenue Growth
+87.3%
EPS Growth
+1837.5%
Gross Margin
83.6%
Net Margin
72.6%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 616M | 329M | 234M | 3M | 7M |
| Gross Profit | 515M | 291M | 220M | 3M | 6M |
| Operating Income | 123M | 42M | 21M | -218M | -345M |
| EBITDA | 134M | 50M | 26M | -213M | -342M |
| Net Income | 447M | 23M | 13M | -224M | -348M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 79M | 180M | 93M | 102M | 299M |
| Total Assets | 1.1B | 578M | 330M | 194M | 380M |
| Total Liabilities | 415M | 355M | 169M | 135M | 142M |
| Shareholder Equity | 648M | 222M | 161M | 59M | 237M |
| Total Debt | 261M | 254M | 111M | 83M | 79M |
| Net Debt | 182M | 74M | 18M | -19M | -220M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
296M
-67.8% YoY
Capital Expenditures
401K
-2764.3% YoY
Free Cash Flow
296M
-68.0% YoY
Key ratios
Gross Margin
83.6%
Operating Margin
20.0%
Net Margin
72.6%
ROE
101.1%
Debt / Equity
0.40x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.